1. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting
- Author
-
Takahisa Sato, Yoji Suzuki, Hiroyuki Amano, Yuko Miura, Kenji Hosoda, Toshihiro Kawai, Hiroshi Ohyama, Y. Kondo, Keiko Nakagomi, Yuta Tokudome, Masao Omata, Hitoshi Mochizuki, Hiroshi Ashizawa, Yoshihiro Isomura, Yuichiro Kojima, Shuntaro Obi, Miho Kanda, and Shinpei Sato
- Subjects
Oncology ,Sorafenib ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Antineoplastic Agents ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,Medicine ,Humans ,Adverse effect ,Fatigue ,Response Evaluation Criteria in Solid Tumors ,Aged ,Retrospective Studies ,Aged, 80 and over ,Hepatology ,business.industry ,Phenylurea Compounds ,Therapeutic effect ,Liver Neoplasms ,Common Terminology Criteria for Adverse Events ,Middle Aged ,medicine.disease ,Proteinuria ,Treatment Outcome ,chemistry ,030220 oncology & carcinogenesis ,Inclusion and exclusion criteria ,Hypertension ,Quinolines ,030211 gastroenterology & hepatology ,Female ,business ,Lenvatinib ,Progressive disease ,medicine.drug - Abstract
Lenvatinib (an inhibitor of vascular endothelial growth factor (GF) receptors 1–3, fibroblast GF receptors 1–4, platelet-derived GF receptor α, rearranged during transfection, and stem cell factor receptor) was non-inferior to sorafenib in a phase 3 (REFLECT) trial of advanced hepatocellular carcinoma. This study examined the efficacy and safety of lenvatinib in a real-world setting. This was a retrospective, multicenter, observational study. Inclusion and exclusion criteria were based on the phase 3 trial, and participants were observed for at least 12 weeks. Therapeutic effect was determined using the modified Response Evaluation Criteria In Solid Tumors (m-RECIST) at the 8th week. Patients received oral lenvatinib 12 mg/day (body weight > 60 kg) or 8 mg/day (body weight
- Published
- 2018